Teknisk analys

Teknisk analys på Evolution Gaming

Teknisk analys på Evolution Gaming

Teknisk analys på Evolution Gaming-aktien som just nu är väldigt i ropet. Long Life Trading analyserar och det ser vid en snabb blick ut som att aktien visar styrka men när man kollar närmare så finns rejält med svaghet.

Läs mer

Teknisk analys på Cell Impact, Fingerprint Cards, Kancera och Synact Pharma

Teknisk analys på Cell Impact, Fingerprint Cards, Kancera och Synact Pharma

Teknisk analys gjord av Long Life Trading på Cell Impact, Fingerprint Cards, Kancera och Synact Pharma i högt tempo. Aktiemarknaden når kritiska nivåer.

Läs mer

Investtech analyserar börsen

Investtech analyserar börsen

Espen Grønstad från den välkända tekniska analys-firman Investtech analyserar börsen och sex olika högriskaktier.

Läs mer

Teknisk analys med Nils Brobacke räntor, valutor, råvaror och aktieindex

Teknisk analys med Nils Brobacke räntor, valutor, råvaror och aktieindex

Nils Brobacke gör teknisk analys på räntor (high yield bonds), valutor, aktieindex och råvaror (bland annat olja och silver). Han går tydligt igenom vilka nivåer som gäller och vad en trader ska göra vid dem.

Läs mer

Erik Hansén förklarar teknisk analys

Erik Hansén förklarar teknisk analys

Erik Hansén ger en snabb förklaring på vad teknisk analys är, varför man använder den och hur den skiljer sig från fundamental analys.

Läs mer

Marknadsnyheter

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

lör, sep 18, 2021 17:31 CET Longest survival follow-up ever reported for immunotherapy treatment in this setting Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for […]

Läs mer

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

lör, sep 18, 2021 15:06 CET Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients DESTINY-Breast01 Phase II trial data also presented at ESMO showed impressive median overall survival of 29.1 months in HER2-positive patients following two or more HER2-based […]

Läs mer

Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

lör, sep 18, 2021 13:31 CET First HER2-directed therapy to show a strong tumour response in this population Data from HER2-mutant cohort of pivotal DESTINY-Lung01 Phase II trial presented at ESMO and published in The New England Journal of Medicine Detailed primary results from the positive Phase II DESTINY-Lung01 trial of Enhertu (trastuzumab deruxtecan), the AstraZeneca […]

Läs mer

Enhertu demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial

Enhertu demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial

fre, sep 17, 2021 18:07 CET First Enhertu trial in Western patients with gastric cancer Efficacy and safety results consistent with registrational DESTINY-Gastric01 will support ongoing discussions with global health authorities Detailed results from the positive Phase II DESTINY-Gastric02 trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed […]

Läs mer

Förtydligande avseende Aegirbios aktiepris och premie i förvärvet av Dynamic Code AB

Förtydligande avseende Aegirbios aktiepris och premie i förvärvet av Dynamic Code AB

fre, sep 17, 2021 18:05 CET AegirBio AB (”AegirBio”) har idag ingått avtal med aktieägare representerande cirka 52,1 procent av samtliga aktier i Dynamic Code AB (publ) (”Dynamic Code”) om förvärv av aktier och teckningsoptioner i Dynamic Code. Köpeskillingen uppgår till 172 kronor per aktie i Dynamic Code, varav 15 kronor betalas kontant och 157 […]

Läs mer

Andra artiklar

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

| 18 september, 2021 | 0 kommentarer

lör, sep 18, 2021 17:31 CET Longest survival follow-up ever reported for immunotherapy treatment in this setting Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for […]

Läs mer

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

| 18 september, 2021 | 0 kommentarer

lör, sep 18, 2021 15:06 CET Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients DESTINY-Breast01 Phase II trial data also presented at ESMO showed impressive median overall survival of 29.1 months in HER2-positive patients following two or more HER2-based […]

Läs mer

Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

| 18 september, 2021 | 0 kommentarer

lör, sep 18, 2021 13:31 CET First HER2-directed therapy to show a strong tumour response in this population Data from HER2-mutant cohort of pivotal DESTINY-Lung01 Phase II trial presented at ESMO and published in The New England Journal of Medicine Detailed primary results from the positive Phase II DESTINY-Lung01 trial of Enhertu (trastuzumab deruxtecan), the AstraZeneca […]

Läs mer